Dear  Friends,

It is with great pleasure that we present to you the third 2011 quarterly issue of the Jerusalem Life Science Bulletin, highlighting the latest achievements and news of Jerusalem’s life science cluster. 

In July, we had the pleasure of hosting a delegation from San Antonio, led by Mayor Julián Castro and including Ann Stevens, President of Biomed SA, San Antonio’s biomed initiative. As America‘s seventh largest city, San Antonio is a regional hub for medical care and one of the nation’s bioscience leaders in key disease areas including diabetes, military and regenerative medicine, the neurosciences, cancer, and infectious diseases, among others. A collaboration agreement was signed between Biomed SA, and Biojerusalem and we are currently working on the its implementation to bring about our vision of mutual benefit to both regions.

In September BioJerusalem took part in an Entrepreneurship Symposium organized by Bioabroad. The Symposium took place in three major U.S life sciences hubs; Boston, Washington D.C. and San Francisco. The purpose of the Symposium was to meet with entrepreneurs who are interested in establishing their businesses in Israel and to provide them with all of the relevant information. Alongside BioJerusalem, the panel of experts included representatives from the Ministry of Industry, Trade and Labor, the Ministry of Immigration Absorption, and Tax and Legal experts. 

The Jerusalem Biomed sector was chosen as the focus of The Jerusalem Economic Forum hosted by Jerusalem Mayor, Nir Barkat. The forum convenes several times per year, focusing each time on a topic of relevance to the city’s economic development. I would like to thank our panel members, Dr. Aharon Schwartz, Prof. Shlomo Mor-Yosef and Prof. Ariel Darvasi, for a very interesting panel discussion.

With  best wishes,

Chen  Levin, Executive Director of BioJerusalem, The Jerusalem Development Authority

BioLineRx  Announces First Subject Enrolled in Phase I Clinical Trial of BL-1021 for  Neuropathic Pain  The primary endpoints of the study are to examine the safety and tolerability  of a single administration or multiple administrations of BL-1021

Intec  Pharma jumps on positive Parkinson’s results   The company’s Levodopa accordion pill was found to greatly improve current  versions of the drug

BioLineRx  Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021  for Neuropathic Pain   Results show the drug is safe and well tolerated

FDA  approves Teva’s Jerusalem facility   A new inspection of the Oral Solid Dosage facility found that it complied with  current Good Manufacturing Practices

Yissum  Introduces Novel Markers for Brain Cancer Survival Prognosis and a New  Treatment Method for the Disease   Findings were published in the prestigious Cancer Research journal

Path to  cure for diabetes opens   Glucose-sensing enzyme holds the key to insulin production

BioMed SA  strikes deal with BioJerusalem    San Antonio  mayor, BioMed SA president co-sign memorandum of intent with Jerusalem  Development Authority initiative to begin building relationships to benefit  biomedical sectors of both regions

Hebrew  University’s Yissum teams with Shaare Zedek Hospital   Yissum CEO Yaacov Michlin:  We’ll be the only commercialization company in Israel that works for both a  university and a hospital

BioMarCare  Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.   BioMarCare and Ariadne Inc. will jointly develop a diagnostic test

BioLineRx  In-Licenses BL-7050   A Novel, Orally-Available Molecule for the Treatment of Neuropathic and  Inflammatory Pain

Hadasit  launches Jewish-Arab biomed incubator in Galilee   Hadasit has pledged to invest NIS  7.5 million in Ways over the next five years

“Large  drug companies are stuck in a rut”   Teva’s new VC fund head Dr.   Aharon Schwartz tells “Globes” about changing  trends in drug development

BioLineRx  Announces Plans to Launch ADR Program on NASDAQ    BioLineRx to list shares through American Depositary Receipts

BioLineRx  ADRs Issues   Begin Trading on NASDAQ

Chief  Scientist approves NIS 5.9m Biocancell pancreatic cancer trial   The FDA has approved a Phase IIb clinical trial (multicenter efficacy trial) of  the BC-819 drug for the treatment of pancreatic cancer

Intec  Pharma raises NIS 10.8m in rights issue   The company, which develops improved versions of current drugs, received orders  for 99.96% of the units offered

http://biojerusalem.org.il/newsletters/q3_2011/

Categories: END TIMES, MEDICAL/SCIENCE

Tags: Aharon Schwartz, Biojerusalem, Israel, Jerusalem, Nir Barkat, San Antonio, San Francisco, Washington D.C.